Abstract
Ebolaviruses continue to pose a significant outbreak threat, and while Ebola virus (EBOV)-specific vaccines and antivirals have been licensed, efforts to develop candidates offering broad species cross-protection are continuing. The use of pseudotyped virus in place of live virus is recognised as an alternative, safer, high-throughput platform to evaluate anti-ebolavirus antibodies towards their development, yet it requires optimisation. Here, we have shown that the target cell line impacts neutralisation assay results and cannot be selected purely based on permissiveness. In expanding the platform to incorporate each of the ebolavirus species envelope glycoprotein, allowing a comprehensive assessment of cross-neutralisation, we found that the recently discovered Bombali virus has a point mutation in the receptor-binding domain which prevents entry into a hamster cell line and, importantly, shows that this virus can be cross-neutralised by EBOV antibodies and convalescent plasma.
Funder
Biotechnology and Biological Sciences Research Council
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Immunology and Microbiology
Reference66 articles.
1. World Health Organisation WHO Situation Report: Ebola Virus Diseasehttp://apps.who.int/iris/bitstream/10665/208883/1/ebolasitrep_10Jun2016_eng.pdf?ua=1
2. Emergence of Zaire Ebola Virus Disease in Guinea
3. WHO List of Blueprint Priority Diseaseshttp://www.who.int/blueprint/priority-diseases/en/
4. Ebola haemorrhagic fever in Zaire, 1976;Johnson;Bull. World Health Organ.,1978
5. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team;Smith;Bull. World Health Organ.,1978
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献